Here’s whether Incyte Genomics Inc (INCY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.14% over 10 days); strong 1-year return of +52.3%; 3-month momentum positive (+5.4%). Currently 8.8% off its 52-week high. Score: +6/7.
INCY is in a confirmed uptrend, trading above both its 50-day ($96.51) and 200-day ($96.00) moving averages. An RSI of 69.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +52.3% compares to +24.4% for SPY (beat the market by 27.9%).
$10,000 invested 1 year ago→ $15,226 today
vs. S&P 500 (SPY) — same period beat market by 27.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($96.00)
✓Above 50-day MA ($96.51)
✓RSI(14) neutral zone (30–70) — currently 69.2
✓Positive return (+52.3%)
✓Within 10% of period high (−8.8%)
Period Range $102.38
$66.74$112.29
RSI (14) 69.2
0 · OversoldOverbought · 100
Key Metrics
Price$102.38
Period Return+52.3%
Period High$112.29
Period Low$66.74
Drawdown−8.8%
MA-50$96.51
MA-200$96.00
RSI (14)69.2
Avg Volume (30d)1.5M
vs. SPYbeat by 27.9%
Return Rank#337 of 1245
Trend Signals
Price is above the 200-day moving average ($96.00)